Inbrain Pharma
InBrain Pharma, a CNS disorders focused biotech, founded in 2018, exploiting through an exclusive worldwide patent license signed with the Northern France TTO, a groundbreaking therapeutic approach of advanced Parkinson’s Disease based on the research work of Pr David DEVOS and Pr Caroline MOREAU developed within their academic research Team from the Université́ de Lille, Lille Neuroscience & cognition UMR-S 1172 INSERM and the Lille University Hospital. To date, the company has raised €4.4 million in dilutive and non-dilutive financing, these funds having enabled to carry out a first phase I/IIb DIVE-I clinical trial on 12 patients, for which results have just been obtained.
7-day free trial · no credit card
Verified contacts
3
available on Kipplo
LinkedIn employees
5
1 to 10 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 3 verified contacts at Inbrain Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
3 contacts with verified email or phone · masked until revealed.
Showing 1 of 3 verified contacts
Top roles at Inbrain Pharma
3 distinct titles indexed · top 3 shown.
- 1chief executive officer
- 1co-fondateur, cso ex-ceo
- 1gerente comercial
Sign up to unlock all 3 contacts at Inbrain Pharma
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 3 verified contacts at Inbrain Pharma
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.